ACER — Acer Therapeutics Share Price
0.000.00%
Last trade - 00:00- $19.68m
- $50.19m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 39.34 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 1.26 | n/a | 8.67 | 48.43 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acer Therapeutics Inc 是一家製藥公司，專注於收購、開發和商業化治療嚴重罕見和危及生命的疾病的藥物，這些藥物的醫療需求尚未得到滿足。該公司的產品管線包括OLPRUVA（苯丁酸鈉）、ACER-801（奧沙奈坦）和EDSIVO（塞利洛爾）。口服混懸液用OLPRUVA（苯丁酸鈉）是一種苯丁酸鈉粉劑，用於治療各種先天性代謝缺陷，包括尿素循環障礙（UCDs）和楓糖漿尿病（MSUD）。其ACER-801（奧沙奈坦）是一種研究性非激素神經激肽三受體（NK3R）拮抗劑，用於治療運動癥狀（VMS）、創傷后應激障礙（PTSD）和前列腺癌。其EDSIVO（塞利洛爾）是一種選擇性腎上腺素能調節劑，用於治療已確認III型膠原蛋白（COL3A1）突變患者的血管性Ehlers-Danlos綜合征（vEDS）。
Directors
- Stephen Aselage NEC (70)
- Christopher Schelling PRE (45)
- Harry Palmin CFO (51)
- Jefferson Davis OTH (54)
- John Klopp OTH (47)
- Matthew Seibt OTH (50)
- Donald Joseph SEC (67)
- Jason Amello IND (52)
- John Dunn IND (69)
- Michelle Griffin IND (55)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- May 15th, 2018
- Public Since
- September 1st, 2006
- No. of Shareholders
- 84
- No. of Employees
- 33
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 24,463,726
- Address
- One Gateway Center (300 Washington St.), NEWTON, 02458
- Web
- https://acertx.com/
- Phone
- Auditors
- BDO USA, LLP
Upcoming Events for ACER
Q4 2023 Acer Therapeutics Inc Earnings Release
Q1 2024 Acer Therapeutics Inc Earnings Release
Acer Therapeutics Inc Annual Shareholders Meeting
Similar to ACER
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Acer Therapeutics share price?
As of Today at 18:00 UTC, shares in Acer Therapeutics are trading at $0.80. This share price information is delayed by 15 minutes.
How has the Acer Therapeutics share price performed this year?
Shares in Acer Therapeutics last closed at $0.80 and the price had moved by -30.71% over the past 365 days. In terms of relative price strength the Acer Therapeutics share price has underperformed the S&P500 Index by -37.3% over the past year.
What are the analyst and broker recommendations for Acer Therapeutics?
The overall consensus recommendation for Acer Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Acer Therapeutics dividend yield?
Acer Therapeutics does not currently pay a dividend.
Does Acer Therapeutics pay a dividend?
Acer Therapeutics does not currently pay a dividend.
When does Acer Therapeutics next pay dividends?
Acer Therapeutics does not currently pay a dividend.
How do I buy Acer Therapeutics shares?
To buy shares in Acer Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acer Therapeutics?
As of the previous close price of $0.80, shares in Acer Therapeutics had a market capitalisation of $19.68m.
Where are Acer Therapeutics shares listed?
Here are the trading details for Acer Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACER
What kind of share is Acer Therapeutics?
Based on an overall assessment of its quality, value and momentum Acer Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acer Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in Acer Therapeutics is $1.50. That is 86.45% above the last closing price of $0.80.
Analysts covering Acer Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.73 for the next financial year.
What is the trend in the Acer Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acer Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -6.75%.
As of the last closing price of $0.80, shares in Acer Therapeutics were trading -20.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acer Therapeutics PE Ratio?
The Acer Therapeutics PE ratio based on its reported earnings over the past 12 months is 39.34. The shares last closed at $0.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acer Therapeutics?
Acer Therapeutics' management team is headed by:
- Stephen Aselage - NEC
- Christopher Schelling - PRE
- Harry Palmin - CFO
- Jefferson Davis - OTH
- John Klopp - OTH
- Matthew Seibt - OTH
- Donald Joseph - SEC
- Jason Amello - IND
- John Dunn - IND
- Michelle Griffin - IND